Metabolism of Propranolol during Percutaneous Absorption in Human Skin
Authors:
- Carmen A. ChowCCCarmen A. Chow
- Ronald C. WesterRWRonald C. Wester
- Howard I. MaibachHMHoward I. Maibach
- 1 August 1993
- journal article
- research article
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 82 (8) , 767-770
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Extent of cutaneous metabolism during percutaneous absorption of xenobioticsToxicology and Applied Pharmacology, 1989
- Propranolol's metabolism is determined by both mephenytoin and debrisoquin hydroxylase activitiesClinical Pharmacology & Therapeutics, 1989
- FDA and AAPS Report of the Workshop on Principles and Practices of In Vitro Percutaneous Penetration Studies: Relevance to Bioavailability and BioequivalencePharmaceutical Research, 1987
- Skin penetration and metabolism of topically applied chemicals in six mammalian species, including man: An in vitro study with benzo6a9pyrene and testosterone*1Toxicology and Applied Pharmacology, 1985
- An in vitro approach to studying cutaneous metabolism and disposition of topically applied xenobioticsToxicology and Applied Pharmacology, 1984
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976
- Clinical Pharmacokinetics of β-Adrenoreceptor Blocking DrugsClinical Pharmacokinetics, 1976
- The pharmacodynamics and metabolism of propranolol in manEuropean Journal of Clinical Pharmacology, 1970
- Metabolism of Propranolol (‘Inderal’), a Potent, Specific β-Adrenergic Receptor Blocking AgentNature, 1967